LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker

Journal of Proteome Research

Volumn 9, Issue 12, 2010, Pages 6180-6190

  He, Yifeng ^a   Wu, Xin ^a   Liu, Xiaohui ^a   Yan, Guoquan ^a   Xu, Congjian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEIN 14 3 3; PROTEIN 14 3 3 ZETA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER INVASION; CANCER MODEL; CANCER PATIENT; DIAGNOSTIC ACCURACY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUPERNATANT; SURVIVAL RATE; TUMOR XENOGRAFT;

14-3-3 PROTEINS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEINS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS MUSCULUS;

EID: 78649902935     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100822v     Document Type: Article

References (36)

1. Boyle, P., Levin, B., Eds. World Cancer Report; IARC Nonserial Publication Series; WHO Press: Geneva, Switzerland, 2008; p 424.
2. Tetsche, M. S.; Dethlefsen, C.; Pedersen, L.; Sorensen, H. T.; Norgaard, M. The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study BMC Cancer 2008, 8, 31
3. Aletti, G. D.; Gallenburg, M. M.; Cliby, W. A.; Jatoi, A.; Hartmann, L. C. Current management strategies for ovarian cancer Mayo Clin. Proc. 2007, 82, 751-770
4. Woodward, E. R.; Sleightholme, H. V.; Considine, A. M.; Williamson, S.; McHugo, J. M.; Cruger, D. G. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective BJOG 2007, 114, 1500-1509
5. Ma, S.; Shen, K.; Lang, J. A risk of malignancy index in preoperative diagnosis of ovarian cancer Chin. Med. J. 2003, 116, 396-399
6. Torres, J. C. C.; Derchain, S. F. M.; Faundes, A.; Gontijo, R. C.; Martinez, E. Z.; de Angelo Andrade, L. A. L. Risk-of-Malignancy Index in preoperative evaluation of clinically restricted ovarian cancer Sao Paulo Med. J./Rev. Paul. Med. 2002, 120, 72-76
7. Doig, T.; Monaghan, H. Sampling the omentum in ovarian neoplasia: when one block is enough Int. J. Gynecol. Cancer 2006, 16, 36-40
8. Kenny, H. A.; Kaur, S.; Coussens, L. M.; Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin J. Clin. Invest. 2008, 118, 1367-1379
9. Petricoin III, E. F.; Ardekani, A. M.; Hitt, B. A.; Levine, P. J.; Fusaro, V. A.; Steinberg, S. M.; Mills, G. B.; Simone, C.; Fishman, D. A.; Kohn, E. C.; Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer Lancet 2002, 359, 572-577 (Pubitemid 34178440)
10. Giuliani, F. C.; Zirvi, K. A.; Kaplan, N. O. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin Cancer Res. 1981, 41, 325-335
11. McDonald, W. H.; Yates, J. R., III Shotgun proteomics and biomarker discovery Dis. Markers 2002, 18, 99-105
12. Ishikawa, Y.; Ishikawa, Y.; Minami, R. Quantitative estimation of dystrophin protein: a sensitive and convenient "two-antibody sandwich" ELISA Tohoku J. Exp. Med. 1996, 180, 57-63
13. Mor, G.; Visintin, I.; Lai, Y.; Zhao, H.; Schwartz, P.; Rutherford, T.; Yue, L.; Bray-Ward, P.; Ward, D. C. Serum protein markers for early detection of ovarian cancer Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7677-7682
14. Lewis, S.; Ashburner, M.; Reese, M. G. Annotating eukaryote genomes Curr. Opin. Struct. Biol. 2000, 10, 349-354
15. Sun, H.; Fang, H.; Chen, T.; Perkins, R.; Tong, W. GOFFA: gene ontology for functional analysis - a FDA gene ontology tool for analysis of genomic and proteomic data BMC Bioinform. 2006, 7 (2) S23
16. Carvalho, P. C.; Fischer, J. S.; Chen, E. I.; Yates, J. R.; Barbosa, V. C. PatternLab for proteomics: a tool for differential shotgun proteomics BMC Bioinform. 2008, 9, 316
17. Diamandis, E. P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations Mol. Cell. Proteomics 2004, 3, 367-378
18. Faça, V. M.; Ventura, A. P.; Fitzgibbon, M. P.; Pereira-Faça, S. R.; Pitteri, S. J.; Green, A. E.; Ireton, R. C.; Zhang, Q.; Wang, H.; O'Briant, K. C.; Drescher, C. W.; Schummer, M.; McIntosh, M. W.; Knudsen, B. S.; Hanash, S. M. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains PLoS One 2008, 3 e2425
19. Gunawardana, C. G.; Kuk, C.; Smith, C. R.; Batruch, I.; Soosaipillai, A.; Diamandis, E. P. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer J. Proteome Res. 2009, 8, 4705-4713
20. Yaffe, M. B.; Rittinger, K.; Volinia, S.; Caron, P. R.; Aitken, A.; Leffers, H.; Gamblin, S. J.; Smerdon, S. J.; Cantley, L. C. The structural basis for 14-3-3: phosphopeptide binding specificity Cell 1997, 91, 961-971
21. Ogihara, T.; Isobe, T.; Ichimura, T.; Taoka, M.; Funaki, M.; Sakoda, H.; Onishi, Y.; Inukai, K.; Anai, M.; Fukushima, Y.; Kikuchi, M.; Yazaki, Y.; Oka, Y. Asano, T. 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain J. Biol. Chem. 1997, 272, 25267-25274
22. Deakin, N. O.; Bass, M. D.; Warwood, S.; Schoelermann, J.; Mostafavi-Pour, Z.; Knight, D.; Ballestrem, C.; Humphries, M. J. An integrin-alpha4-14-3-3zeta-paxillin ternary complex mediates localised Cdc42 activity and accelerates cell migration J. Cell Sci. 2009, 122 (Pt 10) 1654-1664
23. Keshamouni, V. G.; Michailidis, G.; Grasso, C. S.; Anthwal, S.; Strahler, J. R.; Walker, A.; Arenberg, D. A.; Reddy, R. C.; Akulapalli, S.; Thannickal, V. J.; Standiford, T. J.; Andrews, P. C.; Omenn, G. S. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype J. Proteome Res. 2006, 5, 1143-1154
24. Matta, A.; Bahadur, S.; Duggal, R.; Gupta, S. D.; Ralhan, R. Over-expression of 14-3-3zeta is an early event in oral cancer BMC Cancer 2007, 7, 169
25. Sawhney, M.; Matta, A.; Macha, M. A.; Kaur, J.; DattaGupta, S.; Shukla, N. K.; Ralhan, R. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients Int. J. Cancer 2009, 124, 2098-2105
26. Bajpai, U.; Sharma, R.; Kausar, T.; Dattagupta, S.; Chattopadhayay, T. K.; Ralhan, R. Clinical significance of 14-3-3 zeta in human esophageal cancer Int. J. Biol. Markers 2008, 23, 231-237
27. Liang, S.; Singh, M.; Gam, L. H. The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to ethnicity of the patients; Chinese, Malay and Indian Dis. Markers 2010, 28, 149-165
28. Li, Z.; Zhao, J.; Du, Y.; Park, H. R.; Sun, S. Y.; Bernal-Mizrachi, L.; Aitken, A.; Khuri, F. R.; Fu, H. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 162-167
29. Maxwell, S. A.; Li, Z.; Jaya, D.; Ballard, S.; Ferrell, J.; Fu, H. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen J. Biol. Chem. 2009, 284, 22379-22389
30. Washburn, M. P.; Wolters, D.; Yates, J. R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology Nat. Biotechnol. 2001, 19, 242-247 (Pubitemid 32220565)
31. Jiang, X.; Feng, S.; Tian, R.; Han, G.; Jiang, X.; Ye, M.; Zou, H. Automation of nanoflow liquid chromatography-tandem mass spectrometry for proteome analysis by using a strong cation exchange trap column Proteomics. 2007, 7, 528-539
32. Lin, X. J.; Chen, X. C.; Wang, L.; Wei, Y. Q.; Kan, B.; Wen, Y. J.; He, X.; Zhao, X. Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials J. Exp. Clin. Cancer Res. 2007, 26, 467-474
33. Li, S. L.; Ye, F.; Cai, W. J.; Hu, H. D.; Hu, P.; Ren, H.; Zhu, F. F.; Zhang, D. Z. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line J. Cell. Biochem. 2010, 109, 625-633
34. Shenhua, X.; Lijuan, Q.; Hanzhou, N.; Xinghao, N.; Chihong, Z.; Gu, Z.; Weifang, D.; Yongliang, G. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization J. Exp. Clin. Cancer Res. 1999, 18, 233-239
35. Ishiwata, I.; Ishiwata, C.; Soma, M.; Ishikawa, H. Establishment of HUOCA-II, a human ovarian clear cell adenocarcinoma cell line, and its angiogenic activity J. Natl. Cancer Inst. 1987, 78, 667-673
36. Arencibia, J. M.; Schally, A. V. Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line Int. J. Oncol. 2000, 16, 1009-1013